|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0008838,
umls-concept:C0014582,
umls-concept:C0016360,
umls-concept:C0023413,
umls-concept:C0024623,
umls-concept:C0087111,
umls-concept:C0282440,
umls-concept:C1096777,
umls-concept:C1516213,
umls-concept:C1521996,
umls-concept:C1522673
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2007-4-18
|
|
pubmed:abstractText |
Promising findings obtained using a weekly regimen of 5-fluorouracil (5-FU), epidoxorubicin, leucovorin (LV), and cisplatin (PELFw) to treat locally advanced and metastatic gastric cancer prompted the Italian Group for the Study of Digestive Tract Cancer (GISCAD) to investigate the efficacy of this regimen as adjuvant treatment for high-risk radically resected gastric cancer patients.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1460-2105
|
|
pubmed:author |
pubmed-author:AitiniEnricoE,
pubmed-author:ArdizzoiaAntonioA,
pubmed-author:ArnoldiErmenegildoE,
pubmed-author:BarniSandroS,
pubmed-author:BaroneCarloC,
pubmed-author:BerettaGiordano DGD,
pubmed-author:BertettoOscarO,
pubmed-author:CarnaghiCarloC,
pubmed-author:CascinuStefanoS,
pubmed-author:CassanoAlessandraA,
pubmed-author:CatalanoVincenzoV,
pubmed-author:ChiaraSilvanaS,
pubmed-author:CortesiEnricoE,
pubmed-author:FlorianiIreneI,
pubmed-author:FoaPaoloP,
pubmed-author:FrontiniLucianoL,
pubmed-author:GaspariniGiampietroG,
pubmed-author:GiordaniPaoloP,
pubmed-author:Italian Group for the Study of Digestive Tract Cancer,
pubmed-author:LabiancaRobertoR,
pubmed-author:MansuttiMauroM,
pubmed-author:MosconiStefaniaS,
pubmed-author:NardiMarioM,
pubmed-author:PiazzaElenaE,
pubmed-author:PozzoCarmeloC,
pubmed-author:PucciFrancescaF,
pubmed-author:RabbiCarlaC,
pubmed-author:RavaioliAlbertoA,
pubmed-author:RimassaLorenzaL,
pubmed-author:RotaSilviaS,
pubmed-author:SantoroArmandoA,
pubmed-author:SilvaRosa RitaRR,
pubmed-author:SobreroAlbertoA,
pubmed-author:TorriValterV
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
18
|
|
pubmed:volume |
99
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
601-7
|
|
pubmed:dateRevised |
2007-9-26
|
|
pubmed:meshHeading |
pubmed-meshheading:17440161-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17440161-Chemotherapy, Adjuvant,
pubmed-meshheading:17440161-Cisplatin,
pubmed-meshheading:17440161-Disease-Free Survival,
pubmed-meshheading:17440161-Drug Administration Schedule,
pubmed-meshheading:17440161-Epirubicin,
pubmed-meshheading:17440161-Female,
pubmed-meshheading:17440161-Fluorouracil,
pubmed-meshheading:17440161-Humans,
pubmed-meshheading:17440161-Leucovorin,
pubmed-meshheading:17440161-Lymphatic Metastasis,
pubmed-meshheading:17440161-Male,
pubmed-meshheading:17440161-Middle Aged,
pubmed-meshheading:17440161-Neoplasm Invasiveness,
pubmed-meshheading:17440161-Stomach Neoplasms,
pubmed-meshheading:17440161-Survival Analysis
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial.
|
|
pubmed:affiliation |
Universita' Politecnica delle Marche, Via Conca 60020 Ancona, Italy. cascinu@yahoo.com
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Multicenter Study,
Clinical Trial, Phase III
|
